Recent publications · Crossref
5 total works indexed
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
· 2013 · cited 2,878x
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
· 2014 · cited 1,506x
- Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
· 2021 · cited 1,474x
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients
· 2010 · cited 1,151x
- Assessment of the worldwide burden of critical illness: the Intensive Care Over Nations (ICON) audit
· 2014 · cited 1,026x
via Crossref · CC0